XML 62 R50.htm IDEA: XBRL DOCUMENT
v3.20.2

Significant agreements - AstraZeneca Collaboration Agreement (Details) | 1 Months Ended | 3 Months Ended | 6 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
May 31, 2019 employee | May 31, 2018 USD ($) | Aug. 31, 2017 | Nov. 30, 2016 USD ($) employee item | Jun. 30, 2020 USD ($) | Jun. 30, 2019 USD ($) | Jun. 30, 2020 USD ($) | Jun. 30, 2019 USD ($) | Dec. 31, 2019 USD ($) | Jul. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Oct. 31, 2017 USD ($)
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenues |  |  |  |  | $ 1,571,000 | $ 1,522,000 | $ 2,700,000 | $ 7,906,000 |  |  |  |
Deferred revenue |  |  |  |  | 33,082,000 |  | 33,082,000 |  | $ 5,657,000 |  | $ 14,635,000 |
AstraZeneca |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Biological Targets | item |  |  |  | 6 |  |  |  |  |  |  |  |
Term (in years) |  |  | 3 years |  |  |  |  |  |  |  |  |
Term, Bicycle Research Team (in years) |  |  |  | 1 year |  |  |  |  |  |  |  |
Term, AZ Research (in years) |  |  |  | 2 years |  |  |  |  |  |  |  |
Number of FTE | employee |  |  |  | 2 |  |  |  |  |  |  |  |
Collaboration revenues |  |  |  |  | 319,000 | 362,000 | 731,000 | 787,000 |  |  |  |
Deferred revenue |  |  |  |  | 4,807,000 |  | 4,807,000 |  | 4,913,000 |  | $ 4,727,000 |
AstraZeneca | Development milestone |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  | $ 700,000 |  |  |  |  |  |  |  |  |  |
AstraZeneca | Target One |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  |  |  |  | $ 2,000,000
AstraZeneca | Target Two |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  | $ 600,000 |  |  |  |  |  |  |  |
AstraZeneca | Target Three Research License and Related Services |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenues |  |  |  |  | 300,000 | 300,000 | 700,000 | 600,000 |  |  |  |
AstraZeneca | Commercialization license per candidate |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Customer option payment |  |  |  | 8,000,000 |  |  |  |  |  |  |  |
AstraZeneca | Development Milestone | Development milestone |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Customer option payment |  |  |  | 29,000,000 |  |  |  |  |  |  |  |
AstraZeneca | Regulatory Milestone | Regulatory milestone |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Customer option payment |  |  |  | 23,000,000 |  |  |  |  |  |  |  |
AstraZeneca | Commercial milestone | Commercial milestone |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Customer option payment |  |  |  | $ 110,000,000 |  |  |  |  |  |  |  |
AstraZeneca | Minimum |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Term extension (in years) |  |  |  | 12 months |  |  |  |  |  |  |  |
AstraZeneca | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Term extension (in years) |  |  |  | 15 months |  |  |  |  |  |  |  |
AstraZeneca | 2016 Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Biological Targets | item |  |  |  | 2 |  |  |  |  |  |  |  |
Option fee for development and exploitation rights |  |  |  | $ 8,000,000 |  |  |  |  |  |  |  |
Transaction price |  |  |  | $ 1,200,000 |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  | 0 |  | 0 |  | 0 |  |  |
AstraZeneca | 2016 Collaboration Agreement | Target One and Target Two Research License and Related Services |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenues |  |  |  |  | 0 | $ 25,000 | 0 | $ 200,000 |  |  |  |
AstraZeneca | May 2018 Option Exercise |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Biological Targets | item |  |  |  | 4 |  |  |  |  |  |  |  |
Option fee for development and exploitation rights |  | 5,000,000 |  | $ 5,000,000 |  |  |  |  |  |  |  |
Number of FTE | employee | 2 |  |  |  |  |  |  |  |  |  |  |
Customer option payment |  | $ 8,000,000 |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | 5,650,000 |  | 5,650,000 |  |  | $ 6,300,000 |  |
Deferred revenue |  |  |  |  | 4,800,000 |  | 4,800,000 |  | $ 4,900,000 |  |  |
AstraZeneca | May 2018 Option Exercise | Target Three Research License and Related Services |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | 650,000 |  | 650,000 |  |  |  |  |
AstraZeneca | May 2018 Option Exercise | Target 3 Material Right |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | 1,504,000 |  | 1,504,000 |  |  |  |  |
AstraZeneca | May 2018 Option Exercise | Target 4 Material Right |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | 1,204,000 |  | 1,204,000 |  |  |  |  |
AstraZeneca | May 2018 Option Exercise | Target 5 Material Right |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | 1,165,000 |  | 1,165,000 |  |  |  |  |
AstraZeneca | May 2018 Option Exercise | Target 6 Material Right |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | $ 1,127,000 |  | $ 1,127,000 |  |  |  |  |

X
- Definition Represents the period of AZ Research. + References No definition available. + Details
Name: | bcyc_CollaborativeArrangementAzResearchProgramTerm
Namespace Prefix: | bcyc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period of Bicycle Research. + References No definition available. + Details
Name: | bcyc_CollaborativeArrangementBicycleResearchProgramTerm
Namespace Prefix: | bcyc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of biological targets. + References No definition available. + Details
Name: | bcyc_CollaborativeArrangementNumberOfBiologicalTargets
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the renewal period of Research. + References No definition available. + Details
Name: | bcyc_CollaborativeArrangementResearchProgramRenewalTerm
Namespace Prefix: | bcyc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the term of research program. + References No definition available. + Details
Name: | bcyc_CollaborativeArrangementResearchProgramTerm
Namespace Prefix: | bcyc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount to be paid upon exercise of an option by the customer. + References No definition available. + Details
Name: | bcyc_CustomerOptionPayment
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the number of FTE required to be funded by counterparty. + References No definition available. + Details
Name: | bcyc_NumberOfFte
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount to be paid upon exercise of an option by the customer. + References No definition available. + Details
Name: | bcyc_OptionFeeForDevelopmentAndExploitationRights
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of allocated determined transaction price under revenue recognition arrangement. + References No definition available. + Details
Name: | bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcyc_AstrazenecaCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bcyc_AchievementOfMilestoneAxis=bcyc_DevelopmentMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bcyc_TargetOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bcyc_TargetTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bcyc_TargetThreeResearchLicenseAndRelatedServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_GainContingenciesByNatureAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_GainContingenciesByNatureAxis=us-gaap_ResearchAndDevelopmentArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_GainContingenciesByNatureAxis=us-gaap_FavorableRegulatoryActionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bcyc_AchievementOfMilestoneAxis=bcyc_RegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_GainContingenciesByNatureAxis=bcyc_CommercialMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bcyc_AchievementOfMilestoneAxis=bcyc_CommercialMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=bcyc_RespiratoryCardiovascularAndMetabolicMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bcyc_TargetOneAndTwoResearchLinesAndRelatedServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=bcyc_AdditionalFourTargetsOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bcyc_TargetThreeMaterialRightMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bcyc_TargetFourMaterialRightMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bcyc_TargetFiveMaterialRightMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bcyc_TargetSixMaterialRightMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |